Literature DB >> 28778772

Hemodilution on Cardiopulmonary Bypass: Thromboelastography Patterns and Coagulation-Related Outcomes.

Marco Ranucci1, Ekaterina Baryshnikova2, Erika Ciotti2, Matteo Ranucci2, Simona Silvetti2.   

Abstract

OBJECTIVE: Hemodilution has been associated with both hypocoagulability and hypercoagulability in studies based on thromboelastography (TEG). Severe hemodilution during cardiopulmonary bypass (CPB) is a risk factor for morbidity in cardiac surgery. This study investigated the effects of different degrees of hemodilution with CPB on post-CPB TEG parameters and coagulation-related outcomes.
DESIGN: Retrospective cohort study.
SETTING: University research hospital. PARTICIPANTS: The study comprised 793 cardiac surgery patients.
INTERVENTIONS: None.
MEASUREMENTS AND MAIN RESULTS: The patient population was divided into low (LH), moderate (MH), and severe (SH) hemodilution groups based on the hemodilution degree on CPB. Differences in TEG parameters and coagulation-related outcomes were assessed. Patients with SH experienced significantly (p = 0.019) prolonged clotting times (median r-time 6.1 min, interquartile range 5.1-7.4 min) with respect to patients with MH (median r-time 5.8 min, interquartile range 4.8-7 min) and LH (median r-time 5.9 min, interquartile range 4.8-7.2 min). Clot firmness was significantly (p = 0.001) lower in patients with SH (median maximum amplitude 63 mm, interquartile range 57-68 mm) compared with patients with MH (median maximum amplitude 65 mm, interquartile range 61-71 mm) and LH (median maximum amplitude 67 mm, interquartile range 62-74 mm). Patients with SH had higher chest drain blood loss and required more fresh frozen plasma and platelet concentrate transfusions than did patients with MH or LH. Postoperative thromboembolic complications were significantly (p = 0.006) more common in patients with SH (2.6%) than in patients with MH (0%) or LH (0.4%).
CONCLUSIONS: SH on CPB is associated with hypocoagulation, bleeding, and thrombosis-associated worse outcomes.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  cardiac; cardiopulmonary bypass; coagulation; hemodilution; surgery; thromboelastography

Mesh:

Substances:

Year:  2017        PMID: 28778772     DOI: 10.1053/j.jvca.2017.04.014

Source DB:  PubMed          Journal:  J Cardiothorac Vasc Anesth        ISSN: 1053-0770            Impact factor:   2.628


  5 in total

1.  An Agreement Study Between Point-of-Care and Laboratory Activated Partial Thromboplastin Time for Anticoagulation Monitoring During Extracorporeal Membrane Oxygenation.

Authors:  Yuan Teng; Shujie Yan; Gang Liu; Song Lou; Yang Zhang; Bingyang Ji
Journal:  Front Med (Lausanne)       Date:  2022-06-29

2.  Point-of-care viscoelastic coagulation assessment in healthy dogs during the perianesthetic period.

Authors:  Wen H Wang; Alex M Lynch; Julie A Balko; Daniel J Duffy; James B Robertson; Lysa P Posner
Journal:  BMC Vet Res       Date:  2022-09-14       Impact factor: 2.792

Review 3.  The Role of Deep Hypothermia in Cardiac Surgery.

Authors:  Radosław Gocoł; Damian Hudziak; Jarosław Bis; Konrad Mendrala; Łukasz Morkisz; Paweł Podsiadło; Sylweriusz Kosiński; Jacek Piątek; Tomasz Darocha
Journal:  Int J Environ Res Public Health       Date:  2021-07-01       Impact factor: 3.390

4.  Adequacy of hemostatic resuscitation improves therapeutic efficacy of recombinant activated factor VII and reduces reexploration rate for bleeding in postoperative cardiac surgery patients with refractory hemorrhage.

Authors:  Joel T Feih; Janelle J Juul; Joseph R G Rinka; Lisa M Baumann Kreuziger; Paul S Pagel; Justin N Tawil
Journal:  Ann Card Anaesth       Date:  2019 Oct-Dec

5.  Comparison between thromboelastography and the conventional coagulation test in detecting effects of antiplatelet agents after endovascular treatments in acute ischemic stroke patients: A STROBE-compliant study.

Authors:  Chunyang Liang; Yang Yang; Zijun He; Shang Ma; Xuenan Qu; Yongchun Luo; Chunsen Shen; Ruxiang Xu
Journal:  Medicine (Baltimore)       Date:  2020-03       Impact factor: 1.889

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.